^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TAK-186

    i
    Associations
    News

    Trials

    Company:
    Takeda
    Drug class:
    EGFR inhibitor, CD3 agonist
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer (NCT04844073)
    Phase 1/2
    Takeda
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    03/08/2021
    Primary completion :
    09/27/2025
    Completion :
    11/01/2026
    PD-L1 • KRAS • MSI
    |
    MSI-H/dMMR • PD-L1 negative
    |
    TAK-186
    CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia (NCT04891718)
    Phase 1
    Presage Biosciences
    Withdrawn
    Last update posted :
    07/08/2022
    Initiation :
    09/15/2021
    Primary completion :
    06/05/2022
    Completion :
    06/05/2022
    CD8 • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86
    |
    Opdivo (nivolumab) • TAK-186